EGRX—Thanks for remembering by skepticism vis-á-vis the Ryanodex NDA in ETH.
They should have been doing that (even if only for post-marketing purposes), but today's press release strongly suggests that they haven't.
That seems highly unlikely; however, the US does have many locations where hot weather lasts much of the year, so EGRX won't necessarily have to delay the trial until summer 2018.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.